Research Article
Epidemiological Profile of Salivary Gland Tumors in Southern Iranian Population: A Retrospective Study of 405 Cases
Table 5
Distribution of benign and malignant SGTs in different age groups (intervals of 20 years).
| | Age range | Mean age | Age groups (years) | Total | 0-20 | 20-40 | 40-60 | 60-80 | >80 | | %b | (%)a |
| Benign tumors | Pleomorphic adenoma | 7-74 | 40.5 | 14(6.5%) | 103(48.3%) | 68(31.9%) | 28(13.1%) | 0(0%) | 213 | 52.5 | Warthin’s tumor | 29-81 | 59.2 | 0(0%) | 2(3%) | 29(44.6%) | 32(49.2%) | 2(3%) | 65 | 16 | Basal cell adenoma | 33-70 | 54.1 | 0(0%) | 1(6.6%) | 8(53.3%) | 6(40%) | 0(0%) | 15 | 3.7 | Myoepithelioma | 16-56 | 40 | 1(25%) | 0(0%) | 3(75%) | 0(0%) | 0(0%) | 4 | 0.9 | Oncocytoma | 70-74 | 71.6 | 0(0%) | 0(0%) | 0(0%) | 3(100%) | 0(0%) | 3 | 0.7 | Monomorphic adenoma | 48-83 | 65.5 | 0(0%) | 0(0%) | 1(50%) | 0(0%) | 1(50%) | 2 | 0.4 |
| Malignant tumors | Mucoepidermoid carcinoma | 22-95 | 52.6 | 0(0%) | 6(22.2%) | 11(40.7%) | 7(25.9%) | 3(11.1%) | 27 | 6.6 | Adenoid cystic carcinoma | 25-72 | 49.8 | 0(0%) | 7(30.4%) | 8(34.7%) | 8(34.7%) | 0(0%) | 23 | 5.6 | Acinar cell carcinoma | 18-67 | 39.1 | 1(7.1%) | 6(42.8%) | 6(42.8%) | 1(7.1%) | 0(0%) | 14 | 3.4 | Salivary duct carcinoma | 45-78 | 62.2 | 0(0%) | 0(0%) | 2(25%) | 6(75%) | 0(0%) | 8 | 1.9 | Lymphoma | 11-74 | 58.3 | 1(16.6%) | 0(0%) | 1(16.6%) | 4(66.6%) | 0(0%) | 6 | 1.5 | Malignant mixed tumor | 50-81 | 63.4 | 0(0%) | 0(0%) | 2(40%) | 2(40%) | 1(20%) | 5 | 1.2 | Carcinoma ex pleomorphic adenoma | 31-67 | 52.5 | 0(0%) | 1(25%) | 2(50%) | 1(25%) | 0(0%) | 4 | 0.9 | Basal cell adenocarcinoma | 53-62 | 57.6 | 0(0%) | 0(0%) | 2(66.6%) | 1(33.3%) | 0(0%) | 3 | 0.7 | Poorly differentiated carcinoma | 27-76 | 52 | 0(0%) | 1(33.3%) | 1(33.3%) | 1(33.3%) | 0(0%) | 3 | 0.7 | Epithelial myoepithelial carcinoma | 36-82 | 60.6 | 0(0%) | 1(33.3%) | 0(0%) | 1(33.3%) | 1(33.3%) | 3 | 0.7 | Hyalinizing clear cell carcinoma | 36-36 | 36 | 0(0%) | 1(100%) | 0(0%) | 0(0%) | 0(0%) | 1 | 0.2 | Oncocytic carcinoma | 67-67 | 67 | 0(0%) | 0(0%) | 0(0%) | 1(100%) | 0(0%) | 1 | 0.2 | Papillary carcinoma | 58-58 | 58 | 0(0%) | 0(0%) | 1(100%) | 0(0%) | 0(0%) | 1 | 0.2 | Papillary adenocarcinoma | 58-59 | 59 | 0(0%) | 0(0%) | 1(100%) | 0(0%) | 0(0%) | 1 | 0.2 | Adenocarcinoma | 47-47 | 47 | 0(0%) | 0(0%) | 1(100%) | 0(0%) | 0(0%) | 1 | 0.2 | Small cell neuroendocrine carcinoma | 77-77 | 77 | 0(0%) | 0(0%) | 0(0%) | 1(100%) | 0(0%) | 1 | 0.2 | Adenosquamous cell carcinoma | 43-43 | 43 | 0(0%) | 0(0%) | 1(100%) | 0(0%) | 0(0%) | 1 | 0.2 |
|
|
aPercentage in relation with the histopathologic group. bPercentage in relation with total number of cases.
|